Sponsored by:

Nuclear Medicine: Page 177

PET/CT enhances detection of inflammatory bowel disease
By AuntMinnie.com staff writers
A group from the University of Münster in Germany has found that PET/CT may be able to more effectively detect and monitor inflammatory bowel disease such as Crohn's disease and ulcerative colitis, according to research published in the May issue of the Journal of Nuclear Medicine.
May 1, 2013
Shine Medical reaches Mo-99 milestone
By AuntMinnie.com staff writers
Medical isotope firm Shine Medical Technologies announced it has reached a milestone in its development program with Phoenix Nuclear Labs by successfully producing 3 x 1011 neutrons per second with a deuterium-deuterium fusion reaction.
May 1, 2013
Navidea launches Lymphoseek in U.S.
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals has launched its Lymphoseek nuclear medicine imaging agent in the U.S.
April 30, 2013
Lantheus to proceed with flurpiridaz F-18 program
By AuntMinnie.com staff writers
Contrast agent developer Lantheus Medical Imaging plans to proceed with a phase III program for its flurpiridaz F-18 PET radiopharmaceutical, based on an interim analysis of data from its first phase III study.
April 30, 2013
Philips sells 1st PET/MRI to children's hospital
By AuntMinnie.com staff writers
Texas Children's Hospital announced it will be the first children's hospital in the U.S. to use a PET/MRI scanner (Philips Healthcare).
April 29, 2013
GE, Eisai to partner on PET Alzheimer's agent
By AuntMinnie.com staff writers
GE Healthcare has announced a research collaboration with Japanese pharmaceutical firm Eisai.
April 24, 2013
Navidea raises $5.1M in common stock sale
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals has raised $5.1 million in an underwritten sale of common stock.
April 23, 2013
Cell>Point touts cardiac imaging agent trial results
By AuntMinnie.com staff writers
Radiopharmaceutical developer Cell>Point said that results from phase I and IIa studies of its technetium-99m-labeled ethylenedicysteine-glucosamine (99mTc-EC-G) nuclear imaging contrast agent have been favorable for evaluating the presence and severity of coronary artery disease.
April 9, 2013
PET/CT predicts early breast cancer response to chemo
By Wayne Forrest
By using FDG-PET/CT, physicians will be in a better position to noninvasively predict a breast cancer patient's response to treatment after two cycles of neoadjuvant chemotherapy, helping them decide on the next course of action, concluded a study from Germany.
April 9, 2013
FLT-PET could help predict outcome in head and neck cancer
By Wayne Forrest
Change in F-18 fluorothymidine (FLT) uptake on PET during early radiotherapy or chemoradiotherapy is a strong indicator of the long-term outcomes of head and neck cancer patients, Dutch researchers report in the April issue of the Journal of Nuclear Medicine.
April 3, 2013
2013 04 08 16 55 53 884 Flt Pet Figure2 200
President Obama launches brain research initiative
By AuntMinnie.com staff writers
President Barack Obama has debuted a new research initiative aimed at helping researchers discover new ways to treat, cure, and prevent brain disorders such as Alzheimer's disease, epilepsy, and traumatic brain injury.
April 1, 2013
International Isotopes reports lower loss in 2012
By AuntMinnie.com staff writers
Radioisotope manufacturer International Isotopes said that in spite of a 19% reduction in revenue in 2012 compared to 2011, it reduced its net loss by 62%.
March 31, 2013
Previous Page
Page 177 of 440
Next Page